Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure

Circulation

Volumn 110, Issue 24, 2004, Pages 3674-3679

  Nagaya, Noritoshi ^a   Moriya, Junji ^a   Yasumura, Yoshio ^a   Uematsu, Masaaki ^b   Ono, Fumiaki ^a   Shimizu, Wataru ^a   Ueno, Kazuyuki ^a   Kitakaze, Masafumi ^a   Miyatake, Kunio ^a   Kangawa, Kenji ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

Growth substances; Heart failure; Hormones; Nutrition

Indexed keywords

ADRENALIN; GHRELIN; GROWTH HORMONE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOCARDIOGRAPHY; EXERCISE; EXERCISE TEST; FEMALE; FOOD INTAKE; GROWTH HORMONE BLOOD LEVEL; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; LEAN BODY WEIGHT; MALE; MUSCLE ATROPHY; MUSCLE STRENGTH; NORADRENALIN BLOOD LEVEL; OXYGEN CONSUMPTION; PARAMETER; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; BODY WEIGHT; CACHEXIA; CHRONIC DISEASE; EATING; EXERCISE; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMAN GROWTH HORMONE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PEPTIDE HORMONES; PULMONARY VENTILATION; SYMPATHETIC NERVOUS SYSTEM; VENTRICULAR FUNCTION, LEFT;

EID: 20844460120     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000149746.62908.BB     Document Type: Article

References (26)

1. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med. 1994;331:1564-1575.
2. Pittman JG, Cohen P. The pathogenesis of cardiac cachexia. N Engl J Med. 1964;271:403-409.
3. Amato G, Carella C, Fazio S, et al. Body composition, bone metabolism, heart structure and function in growth hormone deficient adults before and after growth hormone replacement therapy at low doses. J Clin Endocrinol Metab. 1993;77:1671-1676.
4. Fuller J, Mynett JR, Sugden PH. Stimulation of cardiac protein synthesis by insulin-like growth factors. Biochem J. 1992;282:85-90.
5. Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 1996;334:809-814.
6. Anker SD, Volterrani M, Pflaum CD, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol. 2001;38:443-452.
7. Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet. 1998;351:1233-1237.
8. Isgaard J, Bergh CH, Caidahl K, et al. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J. 1998;19:1704-1711.
9. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656-660.
10. Nagaya N, Kojima M, Uematsu M, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol. 2001;280:R1483-R1487.
11. Wiley KE, Davenport AP. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol. 2002;136:1146-1152.
12. Nagaya N, Miyatake K, Uematsu M, et al. Hemodynamic, renal and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab. 2001;86:5854-5859.
13. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001;409:194-198.
14. Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes. 2001;50:227-232.
15. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407:908-913.
16. Nagaya N, Uematsu M, Kojima M, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation. 2001;104:1430-1435.
17. Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating levels of ghrelin in the cachexia associated with chronic heart failure. Circulation. 2001;104:2034-2038.
18. Schiller NB, Acquatella H, Ports TA, et al. Left ventricular volume from paired biplane two-dimensional echocardiography. Circulation. 1979;60:547-555.
19. Nagaya N, Uematsu M, Oya H, et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med. 2001;163:887-891.
20. Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone (GH) release in humans. J Clin Endocrinol Metab. 2000;85:4908-4911.
21. Cittadini A, Grossman JD, Napoli R, et al. Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J Am Coll Cardiol. 1997;29:1109-1116.
22. Baldanzi G, Filigheddu N, Cutrupi S, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol. 2002;159:1029-1037.
23. Locatelli V, Rossoni G, Schweiger F, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999;140:4024-4031.
24. Matsumura K, Tsuchihashi T, Fujii K, et al. Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension. 2002;40:694-699.
25. Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet. 2003;361:1077-1083.
26. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050-1053.